(RTTNews) - OncoGenex Pharma (OGXI) advanced in pre-market trading, after reporting positive survival results from phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone.

The stock was up $1.00 just after 9:00 am ET, rallying to $3.25. If pre-market gains hold, the stock will open at its highest level since early October.

OncoGenex Pharmaceuticals announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone, or the OGX-011 arm, compared to docetaxel and prednisone alone, or the control arm, for first-line treatment of metastatic castrate resistant prostate cancer.

The company said that the current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. The median survival was 27.5 months for the patients in the OGX-011 arm and 16.9 months for those in the control arm.

The study results currently indicate that patients in the OGX-011 arm have a death rate approximately 40% lower than patients in the control arm. The current results are based on study data with a median follow-up of approximately 30 months for both arms, the company said.

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved